Skip to content

A clinical trial of Bio-Germanium for the evaluation of efficacy on immune function enhancement and immune cell activation

A clinical trial of Bio-Germanium for the evaluation of efficacy on immune function enhancement and immune cell activation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0002726
Enrollment
130
Registered
2018-03-09
Start date
2018-01-02
Completion date
Unknown
Last updated
2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Experimental Group - Investigational Product (Bio-Germanium) • Ingredient: Bio-Germanium • Type: HPMC capsule • Weight: 300mg/capsule • Directions: 2 capsules, twice a day (1.2

Sponsors

Yonsei University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Healthy male and female volunteers between the ages of 25 to 75 years 2) Screening result for WBC counts in between 4,000 cells/ul and 8,000 cells/ul 3) Volunteers who have agreed to participate in the study and provided a written content by him/herself or through its legal representative

Exclusion criteria

Exclusion criteria: 1) Those under the treatment for clinically significant acute or chronic diseases in cardiovascular, immune, respiratory, liver, biliary, renal, urinary, nervous, musculoskeletal system as well as psychiatric, infectious, hematologic and neoplastic diseases (exceptions can be made under the discretion of the researcher) 2) Those with uncontrolled hypertension (140/90mmHg or higher, measured after 10 minutes of resting) 3) Those with uncontrolled diabetes (fasting blood glucose levels greater than 126mg/dl or those starting diabetes medication within 3 months) 4) Those received vaccination within 3 months before screening 5) Those with blood AST(GOT) or ALT(GPT) levels greater than 120IU/L 6) Those with blood creatinine level greater than 2.4mg/dL for male and 1.8mg/dL for female 7) Those who have consumed within 2 weeks before screening or are currently consuming health supplements that can affect immune function 8) Those under the severe gastrointestinal symptoms such as heartburn, indigestion, and such 9) Those who are pregnant, breastfeeding or planning to become pregnant during this study 10) Those who are oversensitive or allergic to the investigational product 11) Those who plan to participate in other researches during this study 12) Those who participated in other researches within 4 weeks of the start of this study 13) Those who are deemed inappropriate by the researcher

Design outcomes

Primary

MeasureTime frame
WBC(White blood cell) Count;NK(Natural killer) cell activity;Immune related indicator (IFN-?, IL-2, 6, 12, TNF-a, IgG1, IgG2, IgM);Evaluation of improvement by the subjects themselves (Excellent, Good, Unchanged, Worsening, Very aggravated / 5 Step)

Secondary

MeasureTime frame
Adverse reactions;Vital signs (blood pressure, pulse), weight;Body temperature;Clinical pathology examination (hematology, blood chemistry, urinalysis)

Countries

Korea, Republic of

Contacts

Public ContactJungMin Jo

Yonsei University

jm092477@naver.com+82-2-313-8854

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 17, 2026